Pre-made Samrotamab benchmark antibody ( Whole mAb ADC, anti-LRRC15 therapeutic antibody, Anti-LIB Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-505

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-505 Category Tag

Product Details

Pre-Made Samrotamab biosimilar, Whole mAb ADC, Anti-LRRC15 Antibody: Anti-LIB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer.

Products Name (INN Index)

Pre-Made Samrotamab biosimilar, Whole mAb ADC, Anti-LRRC15 Antibody: Anti-LIB therapeutic antibody

INN Name

Samrotamab

Target

LRRC15

Format

Whole mAb ADC

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2017

Companies

AbbVie

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Solid tumours

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

LRRC15

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide